Aggiornamento
Il retinoblastoma
Retinoblastoma
Alfonso D’Ambrosio1, Gianni Coriolani1, Mauro Caini1, Daniela Galimberti1, Sara Giomi1, Silvia Badii1, Silvia Moretti1, Maria Stefania Toti1, Francesca Coccina1, Federica Carra1, Thedora Hadjistilianou2
1Sezione di Oncoematologia Pediatrica, Dipartimento di Pediatria, Ostetricia e Medicina della Riproduzione
2Sezione di Oftalmologia, Centro di Riferimento per il Retinoblastoma, Dipartimento di Chirurgia, Azienda Ospedaliero-Universitaria Senese, Policlinico “Santa Maria alle Scotte”, Siena
Aprile 2013 - pagg. 227 -236
Abstract
Retinoblastoma is the most frequently diagnosed intraocular malignancy in infants.
Recently, there have been significant advances in the management of this disease.
New therapeutic strategies, such as superselective intra-arterial chemotherapy and
periocular/intravitreal chemotherapy, have been added to conservative treatments
with a long consolidated efficacy. All these procedures are available at the Referral
Centre for Retinoblastoma of the University Hospital of Siena. These advances have
been reflected in increased rates of eye salvage and improved visual outcomes,
notwithstanding the primary objective to safeguard the lives of affected children.
This article summarizes the most important clinical and therapeutic aspects of this
malignancy that every paediatrician should be aware of, particularly when retinoblastoma
is suspected in a young patient.
Classificazione MeSH
Contenuto riservato
Per leggere l'articolo completo è necessario effettuare il login.
Non sei ancora registrato? Registrati
Bibliografia
1. Shields CL, Shields JA. Diagnosis and management
of retinoblastoma. Cancer Control
2004;11:317-27.
2. Magnani C. Stima del numero di casi incidenti
di tumore maligno in età pediatrica in
Italia, per regione. Riv Ital Pediatr 1992;18:203-
7.
3. Lohmann R, Gallie B. Revisiting the Model
prototype of inherited cancer. American Journal
of Medical Genetics, Part C. Semin Med
Genet 2004;129:23-8.
4. Jakocieb FA, Tso MOM, Zimmerman LE,
Danis P. Retinoblastoma and intracranial malignancy.
Cancer 1977;39:2048-58.
5. Bader JL, Miller RW, Meadows AT, Zimmerman
LE, Champion AA, Voute PA. Trilateral
retinoblastoma. Lancet 1980;2:582-3.
6. Provenzale JM, Goururangan S, Klintworth
G. Trilateral retinoblastoma: clinical and radiologic
progression. Am J Roentg 2004;183:
505-11.
7. Acquaviva A. La diagnosi precoce di
retinoblastoma: il ruolo del pediatra. Area Pediatrica
2003;7:51-4.
8. American Academy of Ohthalmology. Eye
examination in infants, children and young
adults by pediatricians. Ohpthalmol 2003;110:
860-5.
9. Nelson LB. Dilemma for pediatrician in detecting
retinoblastoma. J of Pediatr Ophthalmol
and Strabismus 2004;41:142.
10. Shields CL, Gorry T, Shields JA. Outcome
of eyes with unilateral sporadic retinoblastoma
based on the initial external findings by
the family and the pediatrician. J Pediatr Ophthalmol
Strabism 2004;41:143-9.
11. Newsham I, Hadjistilianou T, Cavenee
WK. Retinoblastoma, in: “The metabolic and
molecular bases of inherited disease”. Chapter
11, 613 - 642, vol I, McGraw - Hill Editor, 1995.
12. Hadjistilianou T. Retinoblastoma e Rabdomiosarcoma,
in: Oncologia Oculare. Monografie
della Società Oftalmologica Italiana.
I.N.C Editore. Anno XI - N. 1. 115, 136. 1999.
13. Ramzi C, Vinay K, Tucker-Robbins C. Patologic
Basis of disease. Saunders Philadelphia,
USA, 1999.
14. Acquaviva A, Capolongo A, Hadijstilianou
T, Rondelli R, Pession A. Risk and influence
factors for metastases as well as for second
non-ocular tumors in retinoblastoma patients.
Tumors of the Eye, pp. 145-7. Proceeding of
the International Symposium on Tumor of the
Eye. Essen FRG, Sept 21-23, 1989. Edited by
Bornfeld N, Gragoudas ES, Hopping W, Lommatzsch
PK, Wessing A, Zografos L. Amsterdam/
New York: Kugler Publications, 1991.
15. Hadjistilianou T, Martone G, De Francesco
S, Caporossi A. A RET-CAM imaging study of
macular retinoblastoma pre- and post-treatment.
Ophthalmic Resear 2004;36(S1):212.
16. Abramson DH, Ronner HJ, Ellsworth RM.
Second tumor in non irradiated bilateral
retinoblastoma. Am J Ophthalmol 1979;87:
625-7.
17. Sant M, Capocaccia R, Badioni V and the
EUROCARE Workingroup. Survival for
retinoblastoma in Europe. Eur J Cancer 2001;
37:730-5.
18. Hungerford JL, Kingston J, Plowman N.
Orbital recurrence of retinoblastoma. Ophthalmic
Paediatr Genet 1987;8:63-8.
19. Lennox EL, Draper GJ, Sanders BM.
Retinoblastoma: A study of natural history and
prognosis of 268 cases. Br Med J 1975;3:731-4.
20. Abramson DH, Ellsworth RM, Zimmerman
LE. Non ocular cancer in retinoblastoma
survivors. Trans Am Acad Ophthalmol Otolaryngol
1976;81:545.
21. Abramson DH, Ronner HJ, Ellsworth RM.
Second tumor in non irradiated bilateral
retinoblastoma. Am J Ophthalmol 1979;87:
625-7.
22. Abramson DH, Ellsworth RM, Kitchin FD.
Osteogenic sarcoma of the humerus after
cobalt plaque treatment for retinoblastoma.
Am J Ophthalmol 1980;90:374-6.
23. Jakobiec FA, Tso MOM, Zimmerman LE,
Danis P. Retinoblastoma and intracranial malignancy.
Cancer 1977;39:2048-58.
24. Draper GJ, Sanders BM, Kingston JE.
Retinoblastoma and second primary tumors.
Br J Cancer 1986;53:661-71.
25. Lueder GT, Judisch F, O’Gorman TW. Second
non-ocular tumors in survivors of heritable
retinoblastoma. Arch Ophthalmol 1986;
104:372-3.
26. Lohmann DR. RB1 gene mutations in
retinoblastoma. Hum Mutat 1999;14:283-8.
27. Squire J, Phillips RA, Boyce S, Godbout R,
Rogers B, Gallie BL. Isochromosome 6p, a
unique chromosomal abnormality in
retinoblastoma: verification by standard staining
techniques, new densitometric methods,
and somatic cell hybridization. Hum Genet
1984;66:46-53.
28. Oliveros O, Yunis E. Chromosome evolution
in retinoblastoma. Cancer Genet Cytogenet
1995;82:155-60.
29. Sivakumaran TA, Ghose S, Kumar H, Singha
U, Kucheria K. Absence of pericentromeric
heterochromatin (9qh-) in a patient with bilateral
retinoblastoma. Acta Genet Med
Gemellol (Roma) 1997;46:193-8.
30. Pogosianz HE, Kuznetsova LE. Nonrandom
chromosomal changes in retinoblastomas.
Arch Geschwulstforsch 1986;56:135-
43.
31. Huang Q, Choy KW, Cheung KF, Lam DS,
Fu WL, Pang CP. Genetic alterations on chromosome
19, 20, 21, 22, and X detected by loss
of heterozygosity analysis in retinoblastoma.
Mol Vis 2003;9:502-7.
32. Knudson AG. Mutations and Cancer: statistical
Study of Retinoblastoma. Proc Natl
Acad Sci USA 1971;68:820.
33. Di Ciommo D, Gallie BL, Bremner R.
Retinoblastoma: the disease, gene and protein
provide critical leads to understand cancer.
Seminar in Cancer Biology 2000;10:255-69.
34. Mulligan G, Jacks T. The retinoblastoma
gene family: cousins overlapping interests.
Trends Genet 1998;14:223-9.
35. Frend S, Dryia T, Weimberg R. Oncongenes
and tumor-suppressing genes. N Engl J
Med 1988;318:618-22.
36. Abramson DH. The focal treatment of
retinoblastoma with enphasis on xenon arc
photocoagulation. Acta Ophthal Suppl 1989;
194:3-63.
37. De Falco G, Giordano A. pRb2/p130: a new
candidate for retinoblastoma tumor fomation.
Oncogene 2006;25:5333-40.
38. Nenadov-Beck M, Balmer A, Dessing C,
Pica A, Munier F. First-line chemotherapy
with local treatment can prevent externalbeam
irrdiation and enucleation in low stage
intraocular retinoblastoma. J Clin Oncol 2000;
18:2881-7.
39. Shields CL, Shields JA. Basic understanding
of current classification and management
of retinoblastoma. Curr Opin Ophthalmol
2006;17:228-34.
40. DePotter P, Shields CL, Shields JA. Clinical
variations of trilateral retinoblastoma: a report
of 13 cases. J Pediatr Ophthalmol Strabism
1994;31:26-31.
41. Shields CL, Meadows AT, Shields JA, et al.
Chemoreduction for retinoblastoma may prevent
intracranial neuroblastic malignancy (trilateral
retinoblastoma). Arch Ophthalmol
2001;119:1269-72.
42. Moll AC, Imhof SM, Schouten-Van
Meeteren AY, et al. Chemoreduction for
retinoblastoma. Arch Ophthalmol 2003;121:
1513.
43. Hamel P, Heon E, Gallie BL, Budning AS.
Focal therapy in the management of
retinoblastoma: when to start and when to
stop. J AAPOS 2000;4:334-7.
44. Shields CL, Santos M, Diniz W, et al. Thermotherapy
for retinoblastoma. Arch Ophthalmol
1999;117:885-93.
45. Abramson DH, Schefler AC. Transpupillary
thermotherapy as initial treatment for
small intraocular retinoblastoma: technique
and predictor of success. Ophthalmology
2004;111:984-91.
46. Schuler AO, Jurklies C, Heimann H,
Wieland R, Hawers W, Bornfeld N. Thermochemotherapy
in hereditary retinoblastoma.
Br J Ophthalmol 2003;87:90-5.
47. Hadjistilianou T, Martone G, De Francesco
S, Mazzotta C. TTT e TCT nel retinoblastoma.
Atti Congresso annuale SILO, 2004.
48. Abramson DH, Ellsworth RM, Rozakis
GW. Cryotherapy for retinoblastoma. Arch
Ophthalmol 1982;100:1253-6.
49. Abramson DH, Frank CM, Dunkel IJ. A
phase I/II study of subconjunctival carboplatin
for intraocular retinoblastoma. Ophthalmology
1999;106:1947-50.
50. Marr BP, Dunkel IJ, Linker A, Abramson
DH. Periocular carboplatin for retinoblastoma:
long-term report (12 years) on efficacy
and toxicity. Br J Ophthalmol 2012;96:881-3.
51. Kaneko A, Suzuki S. Eye-preservation
treatment of retinoblastoma with vitreous
seeding. Jpn J Clin Oncol 2003;33:601e7.
52. Suzuki S, Kaneko A. Management of intraocular
retinoblastoma and ocular prognosis.
Int J Clin Oncol 2004;9:1e6.
53. Munier FL, Soliman S, Moulin AP, Gaillard
MC, Balmer A, Beck-Popovic M. Profiling
safety of intravitreal injections for retinoblastoma
using an anti-reflux procedure and sterilisation
of the needle track. Br J Ophthalmol
2012;96:1084-7.
54. Shields JA, Shields CL, De Potter.
Cryotherapy for retinoblastoma. Int Ophthalmol
Clin 1993;33:101-5.
55. Merchant TE, Gould CJ, Wilson MW,
Hilton NE, Rodriguez-Galindo C, Haik BG.
Episcleral plaque brachytherapy for retinoblastoma.
Ped Blood Cancer 2004;43: 134-9.
56. Shields CL, de Potter P, Himelstein BP,
Shields JA, Meadows AT, Maris MJ. Chemoreduction
in the initial management of intraocular
retinoblastoma. Arch Ophthalmol 1996;
114:1330-8.
57. Gombos DS, Kelly A, Coen PG, Kingston
JE, Hungerford JL. Retinoblastoma treated
with primary chemotherapy alone: the signifiance
of tumour size, location and age. Br J
Ophthalmol 2002;87:80-3.
58. Shields CL, Mashayekhi A, Cater J, Shelil
A, Meadows AT, Shields JA. Chemoreduction
for retinoblastoma. Analysis of tumor control
and risks for recurrence in 457 tumors. Am J
Ophthalmol 2004;138:329-37.
59. Greenwald MJ, Strauss LC. Treatment of
intraocular retinoblastoma with carboplatin
and etoposide chemotherapy. Ophthalmology
1996;3:1989-97.
60. Reese AB, Hyman G, Tapley N, Forrest
AW. The treatment of Retinoblastoma by X-ray
and triethylene melamine. AMA Arch Ophthalmol
1958;60:897-906.
61. Kiribuchi M. Retrograde infusion of anticancer
drugs to ophthalmic artery for intraocular
malignant tumors. Nippon Ganka
Gakkai Zasshi 1966;70:1829-33.
62. Kaneko A, Suzuki S. Eye. Preservation
treatment of retinoblastoma with vitreous
seeding. Jpn J Clin Oncol 2003;33:601-7.
63. Suzuki S, Kaneko A. Management of intraocular
retinoblastoma and ocular prognosis.
Int J Clin Oncol 2004;9:1-6.
64. Abramson DH, Dunkel IJ, Brodie SE, et al.
A phase I/II study of direct intraarterial (ophthalmic
artery) chemotherapy with melphalan
for intraocular retinoblastoma: initial results.
Ophthalmology 2008;115:1398-404.
65. Abramson DH, Dunkel IJ, Brodie SE, et al.
Superselective Ophthalmic Artery Chemotherapy
as Primary Treatment for Retinoblastoma
(Chemosurgery). Ophthalmology 2010;
117:1623-9.
66. Gobin YP, Dunkel IJ, Marr BP, Brodie SE,
Abramson DH. Intra-arterial chemotherapy
for the management of retinoblastoma: fouryear
experience. Arch Ophthalmol 2011;129:
732-7.
67. Venturi C, Bracco S, Cerase A, et al. Superselective
ophthalmic artery infusion of
melphalan for intraocular retinoblastoma: preliminary
results from 140 treatments. Acta
Ophthalmol 2012 [Epub ahead of print].
Corrispondenza: dambrosio@unisi.it